This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
VenicMAb™ Chimeric Mouse Anti-Canine VEGF Monoclonal Antibody-B08
Product Overview
BioVenic's VenicMAb™ Chimeric Mouse Anti-Canine VEGF Monoclonal Antibody is a chimeric monoclonal antibody combining the constant domains of the Canine IgG2 molecule with mouse variable regions. The variable region was obtained from a mouse immunized with purified, recombinant Human VEGF. The antibody was produced using recombinant antibody technology.
Specifications
Target Information
Canine Vascular Endothelial Growth Factor (VEGF) is a crucial protein involved in angiogenesis, the process by which new blood vessels form from pre-existing ones. This protein plays a significant role in both normal physiological processes and pathological conditions, such as cancer, where it promotes tumor growth by enhancing blood supply. Anti-canine VEGF monoclonal antibodies could be targeted therapies specifically bind to VEGF, inhibiting its activity and thereby preventing tumor vascularization. This could be a potential approach that holds promise for improving cancer treatment outcomes in dogs, offering a more effective and targeted strategy to manage malignancies.
Shipping and Storage
This product is shipped with dry ice. It is recommended to store at -80 °C on receipt (up to 12 months). Avoid repeated freezing and thawing as this may denature the antibody.
Documents
The product is for research use only.
Not for commercial, prophylactic, diagnostic, or therapeutic applications.
References
- Maiolini, Arianna, et al. "Interleukin-6, vascular endothelial growth factor and transforming growth factor beta 1 in canine steroid responsive meningitis-arteritis." BMC Veterinary Research 9 (2013): 1-10.